Widely studied in experimental models, it shows potential for skeletal muscle hypertrophy, cognitive function, regenerative medicine, and sports performance research
#3 Increase Awareness and Reporting of Mental Health Symptoms A recent report , using qualitative and quantitative/mixed methods, social media listening, and AI and Natural Language Processing techniques, assesses GLP-1 RAs and perceived mental health issues by a large number of open web and social media platform customers
The choice of alternative depends on the severity of the reaction, the patient's weight loss goals, comorbidities, and individual risk-benefit assessment
In June, Eli Lilly has announced Phase II results of its SYNERGY-NASH trial in which 54.9% of patients on its dual GLP-1/GIP receptor agonist tirzepatide 5 mg, 51.3% of patients on tirzepatide 10 mg and 51% of patients on tirzepatide 15 mg saw their fibrosis decreaseby at least one stage without their metabolic dysfunction-associated steatohepatitis (MASH) worsening
You might be wondering, Does what I eat while on GLP-1s actually matter? The short answer is yes, but not for the reasons you might think